0001493152-22-017507.txt : 20220622
0001493152-22-017507.hdr.sgml : 20220622
20220622170057
ACCESSION NUMBER: 0001493152-22-017507
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220621
FILED AS OF DATE: 20220622
DATE AS OF CHANGE: 20220622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Resnick Joshua
CENTRAL INDEX KEY: 0001690959
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 221032722
MAIL ADDRESS:
STREET 1: ONE BOSTON PLACE
STREET 2: 201 WASHINGTON STREET, SUITE 3900
CITY: BOSTON
STATE: MA
ZIP: 02108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: FLOOR 18
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
ownership.xml
X0306
4
2022-06-21
0
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001690959
Resnick Joshua
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM,
MA
02451
1
0
0
0
Stock Option (Right to Buy)
12.26
2022-06-21
4
A
0
12500
0
A
2032-06-20
Common Stock
12500
12500
D
The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ George A. Eldridge, Attorney-in-Fact
2022-06-22